According to a report this week a panel voted 8 to 8 on whether a report of 56 individuals offered adequate proof of the potency of Pulminiq. The exterior panel of medical experts were deadlocked on the data as the UK drug producer Chiron waits to hear the FDA’s decision on its medication. The FDA must reach a decision by mid-month on whether or not it shall approve the medication. Drug organization Chiron said it could conduct another five-year research if Pulminiq is given approval. Although the FDA generally follows the information of its voting panelists, such votes rarely result in deadlock.. Chiron back in the news – deadlock over new lung transplant drug The U.S. Food and Drug Administration Agency is still to make a desision on lung transplant treatment Pulminiq.A few of the study’s results had been previously reported at the Culture of Toxicology workshop kept in February and at the International Meeting on Environmental Epidemiology and Publicity held last September. ‘Whenever we began this study we weren’t sure what we’d find, because previously there is very little information regarding fetal contact with PFOS and PFOA. Despite the fact that these chemicals aren’t bioaccumulative in fat, they have become persistent, which probably makes up about their presence in just about any newborn,’ stated Benjamin Apelberg, PhD, lead writer of the research and a study associate in the Bloomberg College of Public Health’s Section of Epidemiology.